Concert Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration lifted the clinical hold on a mid-stage study testing its drug to treat alopecia areata, a type of hair loss.
The company, which will resume enrollment later this month, expects to complete the study in the second half of 2018.